Furthermore, chronic hypoxia increases TRPC6 expression, whereas the ET-1 antagonist bosentan, a common treatment of PAH, lowers TRPC6 expression in pulmonary VSMCs (Kunichika et al., 2004; Lin et al., 2004). The gene discussed is TRPC6; the disease is pulmonary arterial hypertension.